BRAF and colorectal carcinoma: Thus, encorafenib and PLX8384 have similar in vitro activity and downstream pathway inhibition/reactivation profiles in BRAF mutant CRC but possess greater potency than vemurafenib and in some cell lines less time-dependent pathway reactivation.